Molecular evaluation of cytokeratin 20 mRNA expression of transitional cell carcinoma cases

Amaç: Sitokeratinler 20 polipeptitten meydana gelen ve epitel hücrelerinin intermediyal filamentlerinden şekil alan multigenik proteinlerdir. Sitokeratin 20 mRNA ekspresyon seviyesinin mesane kanserinin erken tanısında kantitatif farkı çok önemlidir.Bu çalışmada tümör prognozu ve rekürrensinde Sitokeratin 20 mRNA ekspresyonunun güvenirliliğinin araştırılması amaçlanmıştır. Yöntem ve Gereç: Transizyonel hücre karsinomu tanılı 34 olgu [Ta(2),T1(19),T2(11),T3(1),T4(1)] ve kontrol olarak 10 sağlıklı gönüllü çalışmaya alınmıştır.Sitokeratin 20 mRNA ekspresyonunun kantifikasyonu Revers Transkriptaz PCR ile gerçekleştirilmiştir. Bulgular: Sitokeratin 20 mRNA ekspresyonunun ortalama rölatif oranı transizyonel hücre karsinomu tanılı 34 olguda 11.91±50.01 ve kontrol grubunda 0.07±0.12 olarak bulundu. En yüksek Sitokeratin 20 mRNA ekspresyon değeri 25.62 olarak T1/G2 grubunda görüldü.Sitokeratin 20 mRNA ekspresyonu ve tümör derecesi arasında anlamlı bir korelasyon bulunmadı.Pozitif ve negatif olgu sonuçları cut-off,spesifite ve sensitivite, metodun pozitif,negatif ve total tanı değerleri sırası ile %69.56, %67.65, %85.19, %59.26, %78.00 olarak hesaplandı. ROC (Receiver Operating Characteristic) eğrisi altındaki alan 0.917 (p

Tranzisyonel hücre karsinomlu olgularda sitokeratin 20 mRNA ekspresyonunun değerlendirilmesi

Aim: Cytokeratins are multigenic proteins which consist of twenty polypeptides and are formed by intermediate filament of epithelial cells. The quantitatively stated difference in the level of Cytokeratin 20 mRNA expression is considerable in early detection of bladder carcinoma. This study aimed to evaluate the value of Cytokeratin 20 mRNA expression in tumor prognosis and recurrence. Material and Methods: Thirty-four cases [Ta(2),T1(19),T2(11),T3(1),T4(1)] diagnosed as transitional cell carcinoma and 10 healthy volunteers as control group were recruited. The quantification of Cytokeratin 20 mRNA expression was performed by Reverse Transcriptase PCR. Results: The average relative ratio of Cytokeratin 20 mRNA expression was 11.91±50.01 in 34 cases with transitional cell carcinoma and 0.07±0.12 in control cases. The highest expression of Cytokeratin 20 mRNA was found in T1/G2 as 25.62. No significant correlation was found between the Cytokeratin 20 mRNA expression and tumor grading. The results were determined according to the cut-off, specificity and sensitivity were 69.56% and 67.65%, respectively with positive, negative and total diagnostic values as; 85.19%,59.26% and 78.00%. The area under the Receiver Operating Characteristic curve was 0.917 (p<0.0001). The cut-off value of Cytokeratin 20 mRNA expression that had the sensitivity (82.4%) and the specificity (81.2%) was determined as 0.1224. Conclusion: We suggest that the combination of increased Cytokeratin 20 mRNA expression and pathological tumor classification is an indicator of more aggressive tumor behavior and the cases should be monitored more closely. The evaluation of Cytokeratin 20 mRNA expression in urine samples will be quite useful in the diagnosis of increased Cytokeratin 20 mRNA expression in the cases with papilloma or tumor.

___

  • 1. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33:1075-107
  • 2. Parker SL, Tong T, Bolden S. Wingo PA. Cancer statistics. CA Cancer J Clin 1997; 47:5-27
  • 3. Konety BR, Williams RD. Superficial transitional (Ta/T1/CIS) cell carcinoma of the bladder. BJU Int 2004; 94:18-21
  • 4. Christoph F, Muller M, Schostak M, Soong R, Tabiti K, Miller K. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction. Urology 2004; 64:157–61
  • 5. American Joint Commission on Cancer/Union Internationale Contra Cancer. 1997
  • 6. Coulombe PA, Omary MB. 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol 2002; 14: 110-22
  • 7. Berezowski K, Stastny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol 1996; 9:426-9.
  • 8. Golijanin D, Shapiro A, and Pode D. Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer. J Urol 2000; 164:1922–1925
  • 9. Inoue T, Nakanishi H, Inada K, Hioki T, Tatematsu M, Sugimura Y. Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells. J Urol 2001; 166: 2134–2141
  • 10. Klein A, Zemer R, Buchumensky V, Klaper R, Nissenkorn I. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Cancer 1998; 82:349-54
  • 11. Soyuer I, Sofikerim M, Tokat F, Soyuer S, Ozturk F. Which urine marker test provides more diagnostic value in conjunction with standard cytology- ImmunoCyt/uCyt+ or Cytokeratin 20 expression.Diagn Pathol. 2009; 26: 4:20.
  • 12. Harnden P, Allam A, Joyce AD, Patel A, Selby P, Southgate J. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: Potential for distinguishing recurrent from non-recurrent disease. Histopathology 1995; 27:169–174
  • 13. Buchumensky V, Klein A, Zemer R, Kessler OJ, Zimlichman S, Nissenkorn I. Cytokeratin 20: A new marker for early detection of bladder cell carcinoma. J Urol 1998; 160:1971–1974
  • 14. Rotem D, Cassel A, Lindenfeld N, Mecz Y, Sova Y, Resnick M, Stein A. Urinary cytokeratin 20 as a marker for transitional cell carcinoma. Eur Urol 2000; 37: 601–604
  • 15. Eissa S, Kenawy G, Swellam M, El-Fadle AA, Abd El-Aal AA, El-Ahmady O. Comparison of cytokeratin 20 RNA and angiogenin in voided urine samples as diagnostic tools for bladder carcinoma. Clin Biochem 2004; 37:803-10
  • 16. Southgate J and Harnden P. Cytokeratin 20: A new marker for early detection of bladder cell carcinoma. J Urol 1999; 162: 501–502
  • 17. Eissa S, Swellam M, Shehata H, El-Khouly IM, El-Zayat T, El-Ahmady O. Comparison of CD44 and cytokeratin 20 mRNA in voided urine samples as diagnostic tools for bladder cancer. Clin Biochem. 2008; 41(16-17):1335-41
  • 18. Guo B, Luo C, Xun C, Xie J, Wu X, Pu J.Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR.Exp Oncol. 2009; 31(1):43-7.
  • 19. Pu XY, Wang ZP, Chen YR, Wang XH, Wu YL, Wang HP. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine.J Cancer Res Clin Oncol. 2008; 134(6):659-65
  • 20. Chausovsky G, Luchansky M, Figer A et al. Expression of cytokeratin 20 in the blood of patients with disseminated carcinoma of the pancreas, colon, stomach, and lung. Cancer 1999; 86:2398-405.
Ege Tıp Dergisi-Cover
  • ISSN: 1016-9113
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 1962
  • Yayıncı: Ersin HACIOĞLU